Crohn's disease, sulfasalazine, and mycobacteria.
The in vitro antimycobacterial activities of sulfasalazine and its split products, mesalazine (5-aminosalicylic acid) and sulfapyridine, against 170 mycobacterial strains belonging to 17 species were compared with those of diaminodiphenylsulfone, sulfadimethoxine, olsalazine, and para-aminosalicyclic acid. Only para-aminosalicylic acid showed consistent activity against Mycobacterium tuberculosis. These data suggest that the principle of activity of sulfasalazine in Crohn's disease is not an antimycobacterial effect.
Van Caekenberghe
D
D
Department of Medical Microbiology, Military Hospital, Brussels, Belgium.
D003424:Crohn Disease / Q000188:drug therapy / Q000382:microbiology*; D006801:Humans; D008826:Microbial Sensitivity Tests; D009161:Mycobacterium / Q000187:drug effects*; D009169:Mycobacterium tuberculosis / Q000187:drug effects; D013329:Structure-Activity Relationship; D012460:Sulfasalazine / Q000494:pharmacology*; D013449:Sulfonamides / Q000494:pharmacology*
D013449:Sulfonamides; D012460:Sulfasalazine